In vitro comparison of the hemocompatibility of two centrifugal left ventricular assist devices.

08:00 EDT 6th August 2018 | BioPortfolio

Summary of "In vitro comparison of the hemocompatibility of two centrifugal left ventricular assist devices."

Shear stress from left ventricular assist devices induces von Willebrand factor degradation and platelet dysfunction, leading to nonsurgical bleeding. We characterized the hemostatic changes induced by 2 centrifugal left ventricular assist devices, the HeartMate 3 (Abbott Inc, Chicago, Ill) and the EVAHEART (Evaheart Inc, Houston, Tex), for comparison.


Journal Details

This article was published in the following journal.

Name: The Journal of thoracic and cardiovascular surgery
ISSN: 1097-685X


DeepDyve research library

PubMed Articles [13311 Associated PubMed Articles listed on BioPortfolio]

Incidence, predictors and clinical impact of electrical storm in patients with left ventricular assist devices: new insights from the ASSIST-ICD study.

Ventricular arrhythmias (VAs) can occur after continuous-flow left ventricular assist devices (LVAD) implantation, as a single arrhythmic event, or as an electrical storm (ES) with multiple repetitive...

Coping, Mood, Quality of Life and Outcomes in Recipients of Left Ventricular Assist Devices: a Cluster Analysis.

Left Ventricular Assist Devices (LVAD) are increasingly used for temporary circulatory support until transplant or as destination therapy (DT) for patients with end-stage Heart failure (HF). Understan...

Increases in Serum Autoantibodies Following Left Ventricular Assist Device Implantation.

Left ventricular assist devices (LVADs) can serve as a bridge to transplant and/or destination therapy for patients with advanced heart failure. Implantation of LVADs is known to be associated with in...

Racial Disparities in Patients Bridged to Heart Transplantation with Left Ventricular Assist Devices.

Left ventricular assist devices (LVADs) are an effective therapy in bridging patients with end stage heart failure to heart transplantation. The aim of this study was to identify the role of race in s...

A case of HeartMate II implantation in non-dilated left ventricle.

Left ventricular assist device is an established therapeutic option for the patient with end-stage heart failure. Recently, durable continuous-flow devices have replaced earlier generation of pulsatil...

Clinical Trials [7834 Associated Clinical Trials listed on BioPortfolio]

Investigation to Optimize Hemodynamic Management of Left Ventricular Assist Devices Using the CardioMEMS™

This observational post market study is intended to characterize hemodynamic-guided management of patients with an existing left ventricular assist device (LVAD) to protocol specified targ...

Determination of Risk Factors of Ventricular Arrhythmias (VAs) After Implantation of Continuous Flow Left Ventricular Assist Device With Continuous Flow Left Ventricular Assist Device (CF-LVAD)

Determination of risk factors of ventricular arrhythmias (VAs) after implantation of continuous flow left ventricular assist device in order to characterize which patient requires ICD impl...

Effects of Echo-optimization of Left Ventricular Assist Devices on Functional Capacity (VAFRACT)

After the implantation of a left ventricular assist device (LVAD), many patients continue to experience exercise intolerance. LVAD echo guided optimization (EO) determines a more favorable...

Stem Cell Therapy in Patients With Severe Heart Failure & Undergoing Left Ventricular Assist Device Placement

The purpose of this study is to determine if the delivery of cells just after implantation of left ventricular assist device will help to improve the pumping function of your heart and min...

Serial Infusions of Allogeneic Mesenchymal Stem Cells in Ischemic Cardiomyopathy Patients With Left Ventricular Assist Device

A study to assess the safety and preliminary efficacy of serial intravenous dose of Allogeneic Mesenchymal Bone Marrow Cells in subjects with ischemic heart failure and implanted left vent...

Medical and Biotech [MESH] Definitions

A form of CARDIAC MUSCLE disease, characterized by left and/or right ventricular hypertrophy (HYPERTROPHY, LEFT VENTRICULAR; HYPERTROPHY, RIGHT VENTRICULAR), frequent asymmetrical involvement of the HEART SEPTUM, and normal or reduced left ventricular volume. Risk factors include HYPERTENSION; AORTIC STENOSIS; and gene MUTATION; (FAMILIAL HYPERTROPHIC CARDIOMYOPATHY).

Rare congenital cardiomyopathies characterized by the lack of left ventricular myocardium compaction. The noncompaction results in numerous prominent trabeculations and a loose myocardial meshwork (spongy myocardium) in the LEFT VENTRICLE. Heterogeneous clinical features include diminished systolic function sometimes associated with left ventricular dilation, that presents either neonatally or progressively. Often, the RIGHT VENTRICLE is also affected. CONGESTIVE HEART FAILURE; PULMONARY EMBOLISM; and ventricular ARRHYTHMIA are commonly seen.

Absence of the orifice between the RIGHT ATRIUM and RIGHT VENTRICLE, with the presence of an atrial defect through which all the systemic venous return reaches the left heart. As a result, there is left ventricular hypertrophy (HYPERTROPHY, LEFT VENTRICULAR) because the right ventricle is absent or not functional.

A condition in which the LEFT VENTRICLE of the heart was functionally impaired. This condition usually leads to HEART FAILURE; MYOCARDIAL INFARCTION; and other cardiovascular complications. Diagnosis is made by measuring the diminished ejection fraction and a depressed level of motility of the left ventricular wall.

Enlargement of the LEFT VENTRICLE of the heart. This increase in ventricular mass is attributed to sustained abnormal pressure or volume loads and is a contributor to cardiovascular morbidity and mortality.

Quick Search

DeepDyve research library

Relevant Topics

Mental Health
Adhd Anorexia Depression Dyslexia Mental Health Psychiatry Schizophrenia Stress Mental health, although not being as obvious as physical health, is very important, causing great unhappiness to those affected, causing add...

The 11th largest pharmaceutical company in the world, <!--LGfEGNT2Lhm-->Abbott Laboratories generated sales of $16 billion in 2009 and has 90,000 employees. Within the <!--LGfEGNT2Lhm-->medical device arm of the company, products of note ar...

Searches Linking to this Article